Skip to main content
SpringerLink
Log in

Allogeneic Peripheral Blood Progenitor Cell Transplantation in Solid Tumors

  • Chapter
Advances in Allogeneic Hematopoietic Stem Cell Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 101))

Abstract

High-dose chemotherapy and autologous transplantation is used as treatment for selected solid tumors, such as breast and ovarian cancer. This approach produces high complete response rates but relapse of the malignancies remains the major problem. This is generally due to incomplete eradication of the disease by high-dose chemotherapy. In addition, autologous transplantation may be contaminated by malignant cells that may contribute to systemic relapse. Allogeneic peripheral blood progenitor cells (PBPC) or bone marrow transplantation has been associated with an immune graft-vs-malignancy effect against leukemias and lymphomas. However, it is uncertain whether a similar graft-vs-malignancy effect will occur against solid tumors. Preliminary trials of allogeneic transplantation have been performed in patients with various solid tumors with the goal of inducing graft-vs-malignancy effects. In this chapter, we will review the rationale and our recent experience of allogeneic transplantation for metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Antman K, Rowling PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.

    PubMed  CAS  Google Scholar 

  2. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309–1317.

    PubMed  CAS  Google Scholar 

  3. Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, Bay JO, Sol C, Canis M, Condat P, Choufi B, Tavernier F, Glenat C, Chollet P, Plagne R. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302–1308.

    PubMed  CAS  Google Scholar 

  4. Lotz JP, Andre T, Donsimoni R, Firmin C, Bouleuc C, Bonnak H, Merad Z, Esteso A, Gerota J, Izrael V. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995; 75: 874–885.

    Article  PubMed  CAS  Google Scholar 

  5. Droz JP, Pico JL, Kramar A. Role of autologous bone marrow transplantation in germ-cell cancer. Urol Clin North Am 1993; 20: 161–171.

    PubMed  CAS  Google Scholar 

  6. Lazarus HM. Autologous bone marrow transplantation for the treatment of lung cancer. Semin Oncol 1993; 20(5 Suppl 6): 72–79.

    PubMed  CAS  Google Scholar 

  7. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920–926.

    Article  PubMed  CAS  Google Scholar 

  8. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383.

    PubMed  CAS  Google Scholar 

  9. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen wE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous transplantation. J Clin Oncol 1996; 14: 1868–1876.

    PubMed  CAS  Google Scholar 

  10. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro MH, Childs BH, Gillio AP, Kernan NA, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    PubMed  CAS  Google Scholar 

  11. Giralt S, Hester J, Huh Y, Hirsch GC, Rondon G, Seong D, Lee M, Gajewski J, Van BK, Khouri I, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–4343.

    PubMed  CAS  Google Scholar 

  12. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    PubMed  CAS  Google Scholar 

  13. Kumar L. Donor leucocyte infusions for relapse in chronic myelogenous leukaemia. Lancet 1994; 344: 1101–1102.

    Article  PubMed  CAS  Google Scholar 

  14. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.

    Article  PubMed  CAS  Google Scholar 

  15. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.

    PubMed  CAS  Google Scholar 

  16. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 1993; 10: 427–432.

    Article  PubMed  CAS  Google Scholar 

  17. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van TP, Horowitz MM, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.

    PubMed  CAS  Google Scholar 

  18. Bar BM, Schattenberg A, Mensink EJ, Geurts VKA, Smetsers TF, Knops GH, Linders EH, De WT. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513–519.

    PubMed  CAS  Google Scholar 

  19. Brenner MK, Heslop HE. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol 1991; 4: 727–749.

    Article  PubMed  CAS  Google Scholar 

  20. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299–307.

    Article  PubMed  Google Scholar 

  21. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096–1102.

    PubMed  Google Scholar 

  22. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    PubMed  CAS  Google Scholar 

  23. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28–30.

    Article  PubMed  CAS  Google Scholar 

  24. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia (published erratum appears in Blood 1989 Aug 15; 74(3): 1180). Blood 1989; 73: 1720–1728.

    PubMed  CAS  Google Scholar 

  25. Champlin RE. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. (Review) (81 refs). Cancer Treatment & Research 1990; 50: 99–111.

    Article  CAS  Google Scholar 

  26. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.

    PubMed  CAS  Google Scholar 

  27. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi G, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986–993.

    PubMed  CAS  Google Scholar 

  28. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Peterson F, Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508.

    PubMed  CAS  Google Scholar 

  29. Obion DJ, Paul S, Oblon MB, Yankee R. Allogeneic peripheral blood stem cell transplants: preliminary results. Blood 1994; 84, Suppl 1: 94a: 366.

    Google Scholar 

  30. Carella AM, Frassoni F, Di Stefano F, Celesti R, Corsetti MT, Lerma E, Celesti L, Dejana A, Gualandi F, Van Lint MT, Bacigalupo A. Engraftment of allogeneic stem cells after nonmyeloablative chemotherapy with fludarabine-containing regime. Proc Amer Soc Clin Oncol 1998; 17:131a (503).

    Google Scholar 

  31. Peters WP, Jones RB, Vredenburdgh J, Shpall EJ, Hussein A, Elkordy M, Rubin P, Ross M, Affronti ML, Moore S, Barry D. Large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for complete remission after intensive doxorubicin-based induction therapy (AFM). Breast Cancer Res Treat 1996; 37:35 (11).

    Google Scholar 

  32. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–2489.

    PubMed  CAS  Google Scholar 

  33. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–1216.

    PubMed  CAS  Google Scholar 

  34. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support (published erratum appears in Cancer 1994 Jul 15; 74(2):773). Cancer 1994; 73: 2157–2167.

    Article  PubMed  CAS  Google Scholar 

  35. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei Er, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–2049.

    PubMed  CAS  Google Scholar 

  36. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast. J Clin Oncol 1997; 15: 3171–3177.

    PubMed  CAS  Google Scholar 

  37. Gabrilovich DI, Kavanaugh D, Corak J, Nadaf-Rahrov S, Cunningham T, Carbone DP. Defective function of dendritic cells in patients with breast cancer can be overcome by generation of these cells from precursors, a new approach to cancer immunotherapy (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A1040.

    Google Scholar 

  38. Savary CA, Graiutti ML, Melichar B, Przepiorka D, Freedman RS, Cowart RE, Chen DM, Anaissie EJ, Woodside DG, Mclntyre BW, Pierson DL, Pellis NR, Rex JH. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 1997; in press:.

    Google Scholar 

  39. Yamasaki S, Kan N, Mise K, Harada T, Ichinose Y, Moriguchi Y, Kodama H, Satoh K, Ohgaki K, Tobe T. Cellular interaction against autologous tumor cells between IL-2-cultured lymphocytes and fresh peripheral blood lymphocytes in patients with breast cancer given immuno-chemotherapy. Biotherapy 1993;6: 63–71.

    Article  PubMed  CAS  Google Scholar 

  40. Hakim AA. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors. Cancer 1988; 61: 689–701.

    Article  PubMed  CAS  Google Scholar 

  41. Arduino S, Tessarolo M, Bellino R, Colombatto S, Leo L, Wierdis T, Lanza A. Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse. European Journal of Gynaecological Oncology 1996; 17: 535–537.

    PubMed  CAS  Google Scholar 

  42. Konjevic G, Spuzic I. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma 1993;40: 81–85.

    PubMed  CAS  Google Scholar 

  43. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372–6380.

    PubMed  CAS  Google Scholar 

  44. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadler LM. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367–1370.

    Article  PubMed  CAS  Google Scholar 

  45. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–1456.

    Article  PubMed  CAS  Google Scholar 

  46. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 1994; 16: 216–223.

    Article  PubMed  CAS  Google Scholar 

  47. Budd GT, Osgood B, Barna B, Boyett JM, Finke J, Medendorp SV, Murthy S, Novak C, Sergi J, Tubbs R, et al. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects. Cancer Res 1989; 49: 6432–6436.

    PubMed  CAS  Google Scholar 

  48. Israel L, Cour V, Pihan I, Morere JF, Breau JL, Franks CR, Palmer P, Loriaux E. Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2. Cancer Treat Rev 1989; 16(Suppl A): 169–171.

    Article  PubMed  Google Scholar 

  49. Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 1982;42: 913–918.

    PubMed  CAS  Google Scholar 

  50. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 1985; 75: 67–75.

    PubMed  CAS  Google Scholar 

  51. Grimm EA, Wilson DJ. The human lymphokine-activated kilier cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 1985; 94: 568–578.

    Article  PubMed  CAS  Google Scholar 

  52. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor PJ, McKenzie IF, Bast RJ, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51: 2908–2916.

    PubMed  CAS  Google Scholar 

  53. Celis E, Tsai V, Crimi C, De MR, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91: 2105–2109.

    Article  PubMed  CAS  Google Scholar 

  54. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994; 74: 1275–1282.

    Article  PubMed  CAS  Google Scholar 

  55. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995; 155: 4486–4491.

    PubMed  CAS  Google Scholar 

  56. Chakravarty PK, Sinha DK. Inhibition of mammary tumorigenesis in virgin rats by adoptive transfer of splenocytes from parous donors. Cancer Immunol Immunother 1991; 33: 263–266.

    Article  PubMed  CAS  Google Scholar 

  57. Mazumder A, Verma U, Areman E, Rajagopal C, Cahill R, Swain S. Peripheral blood stem cell (PBSC) transplantation in breast cancer patients with interleukin-2 (IL-2) activated PBSC leads to visceral graft vs host disease (GVHD) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1994;13: A91.

    Google Scholar 

  58. Areman EM, Mazumder A, Kotula PL, Verma UN, Rajagopal C, Hancock S, Guevarra C, Djahanmir M, Sacher RA, Meehan KR. Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplantation 1996; 18: 521–525.

    PubMed  CAS  Google Scholar 

  59. Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother 1983; 15: 1–10.

    Article  PubMed  CAS  Google Scholar 

  60. Verma UN, Bagg A, Brown E, Mazumder A. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplantation 1994; 13: 115–123.

    PubMed  CAS  Google Scholar 

  61. Shpall EJ, Jones RB, Bearman S. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. Curr Opin Oncol 1994; 6: 135–138.

    Article  PubMed  CAS  Google Scholar 

  62. Verma UN, Charak BS, Rajagopal C, Mazumder A. Interleukin-2 in bone marrow transplantation. (99 Refs). Cancer Treatment & Research 1995; 76: 315–336.

    Article  CAS  Google Scholar 

  63. Verma UN, Meehan KR, Mazumder A. Post-bone marrow transplant use of immunotherapy. (158 Refs). (Review). Cancer Treatment & Research 1997; 77: 27–55.

    Article  CAS  Google Scholar 

  64. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478–484.

    PubMed  CAS  Google Scholar 

  65. Kennedy MJ, Jones RJ. Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation. Breast Cancer Res Treat 1993; 26(Suppl): S31–S40. Review.

    Article  PubMed  Google Scholar 

  66. Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR, O’Donnell MR, Nademanee AP, Snyder DS. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 1987;19: 2605–2607.

    PubMed  CAS  Google Scholar 

  67. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Bherz DL, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Geary K, Champlin R, van Besien K, Andersson B, Maher R, Fitzsimmons W. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host diseasee after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383–4389.

    PubMed  CAS  Google Scholar 

  68. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994;13: 461–464.

    PubMed  CAS  Google Scholar 

  69. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–178.

    PubMed  CAS  Google Scholar 

  70. Masur H. Prevention and treatment of Pneumocystis pneumonia (published erratum appears in N Engl J Med 1993 Apr 15; 328(15):1136). N Engl J Med 1992; 327: 1853–1860.

    Article  PubMed  CAS  Google Scholar 

  71. Przepiorka D, Selvaggi K, Rosenzweig PQ, Borochovitz D, Taylor D. Aerosolized pentamidine for prevention of Pneumocystis pneumonia after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 324–325.

    PubMed  CAS  Google Scholar 

  72. Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 283–288.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA

    Naoto T. Ueno, Gabriel N. Hortobagyi & Richard E. Champlin

Authors
  1. Naoto T. Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard E. Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University Medical Center, Chicago, USA

    Richard K. Burt  & Mary M. Brush  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ueno, N.T., Hortobagyi, G.N., Champlin, R.E. (1999). Allogeneic Peripheral Blood Progenitor Cell Transplantation in Solid Tumors. In: Burt, R.K., Brush, M.M. (eds) Advances in Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 101. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4987-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4987-1_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7264-6

  • Online ISBN: 978-1-4615-4987-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation